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Abstract 
Review on Renal cell carcinoma with 
t(X;17)(p11;q23) CLTC/TFE3, with data on clinics, 
and the genes involved. 
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Identity 
Other names 
Renal cell carcinoma with CLTC-TFE3 gene fusion 
Classification 
This renal cell carcinoma, of which there is only a 
single reported case, belongs to the family of Xp11 
translocation renal carcinomas. Xp11 translocation 
renal cell carcinoma (RCCs) harbor gene fusions 
involving TFE3 transcription factor.   
The t(6;11) RCCs harbor a specific MALAT1 
(Alpha) - TFEB gene fusion.   
TFEB and TFE3 belong to the same MiT subfamily 
of transcription factors.  
Because of similarities at the clinical, morphologic, 
immunohistochemical, and genetic levels, the Xp11 
translocation RCCs and t(6;11) RCCs are currently 
grouped together under the category of  MiT family 
translocation renal cell carcinoma. 
Clinics and pathology 
Etiology 
Unclear. 
Epidemiology 
Single case report in a 14 year old male. 
Pathology 
The tumor was bounded by a calcified fibrous 
pseudocapsule. The tumor had predominantly a 
solid, compact nested pattern, as islands of tumor 
cells were demarcated by fibrovascular septa. More 
dyscohesive areas yielded a papillary architecture. 
Focal calcifications, some in the form of psammoma 
bodies, were frequent, often associated with hyaline 
nodules. Tumor cells were polygonal with well-
demarcated, predominantly clear, voluminous 
cytoplasm. However, there were scattered areas in 
which the cells were smaller and others where they 
demonstrated densely eosinophilic cytoplasm; the 
latter areas had a nested growth pattern and foci of 
central necrosis, somewhat reminiscent of 
hepatocellular carcinoma. Mitoses were sparse. 
Immunohistochemical (IHC) analysis showed strong 
and diffuse nuclear labeling with a polyclonal 
antibody to the TFE3 C-terminal portion, as seen in 
other tumors associated with TFE3 gene fusions.  
Since native TFE3 protein is not detectable in non-
neoplastic cells by the same assay, this finding is 
consistent with constitutive expression of a nuclear 
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fusion protein containing the TFE3 C-terminal 
portion, such as the predicted CLTC-TFE3 protein. 
Like most conventional (clear cell) and papillary 
RCCs, the tumor contained tumor cells were strongly 
and diffusely immunoreactive for CD10, showing 
strong cytoplasmic staining with membranous 
accentuation. However, unlike most typical adult 
RCCs, IHC with all cytokeratin antibodies (Cam5.2, 
AE1/3, Cytokeratin 7) and the "RCC" monoclonal 
antibody yielded negative reactions, though tumor 
cells did label in one isolated area for Epithelial 
Membrane Antigen (EMA).  
Underexpression of common epithelial proteins is a 
typical feature of Xp11.2-translocation carcinomas. 
Surprisingly, the tumor was focally immunoreactive 
for the melanocytic proteins Melan-A and HMB45 
but IHC assays for MiTF and S100 protein were 
negative. While unusual, the immunoreactivity for 
melanocytic markers can be seen in Xp11 
translocation carcinomas. 
Treatment 
Nephrectomy. 
Prognosis 
Unclear. 
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Genes involved and 
proteins 
Note 
The t(X;17)(p11.2;q23) results in a CLTC/TFE3 
gene fusion. 
TFE3 (transcription factor E3) 
Location Xp11.23 
DNA / RNA 
The TFE3 gene includes a 5¹ untranslated region, 8 
exons, and a 3¹ untranslated region. 
Protein 
TFE3 is a transcription factor with a basic helix-
loop-helix DNA binding domain and a leucine 
zipper dimerization domain. TFE3 contains a 
nuclear localization signal, encoded at the junction 
of exons 5 and 6, which is retained within all known 
TFE3 fusion proteins. TFE3 protein is 575 amino 
acids, and is ubiquitously expressed. 
TFE3, TFEB, TFEC and Mitf comprise the members 
of the microphthalmia transcription factor 
subfamily, which have homologous DNA binding 
domains and can bind to a common DNA sequence. 
These four transcription factors may homo- or 
heterodimerize to bind DNA, and they may have 
functional overlap. 
CLTC (clathrin heavy polypeptide) 
Location 17q23.1 
Note 
Clathrin is the major protein constituent of the coat 
that surrounds organelles (cytoplasmic vesicles) to 
mediate selective protein transport. Clathrin coats 
are involved in receptor-mediated endocytosis and 
intracellular trafficking and recycling of receptors, 
which accounts for its characteristic punctate  
cytoplasmic and perinuclear cellular distribution. 
Structurally, clathrin is a triskelion (three-legged) 
shaped protein complex that is composed of a trimer 
of heavy chains (CLTC) each bound to a single light 
chain. CLTC is a 1675 amino acid residue protein 
encoded by a gene consisting of 32 exons. Its known 
domains include a N-terminal globular domain 
(residues 1-494) that interacts with adaptor proteins 
(AP-1, AP-2, b-arrestin), a light chain-binding 
region (residues 1074-1552), and a trimerization 
domain (residues 1550-1600) near the C-terminus. 
Result of the chromosomal 
anomaly 
Fusion Protein 
Description 
In the CLTC-TFE3 fusion, the fusion point on CLTC 
is at amino acid 932 (corresponding to the end of 
exon 17), thereby excluding the CLTC trimerization 
domain from the predicted fusion protein. As in 
other TFE3 gene fusions, the nuclear localization 
and DNA binding domains of TFE3 are retained in 
CLTC-TFE3. Based on these features and existing 
data on other TFE3 fusion proteins, CLTC-TFE3 
may act as an aberrant transcription factor, with the 
CLTC promoter driving constitutive expression. 
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